Scholarlink

<p>To assess associations between blood nicotinamide adenine dinucleotide (NAD) levels and laboratory parameters at baseline and after 60&#xa0;days of nicotinamide mononucleotide (NMN) supplementation. Post hoc analysis of a randomized, double-blind, clinical trial of daily NMN (300, 600, or 900&#xa0;mg) or placebo in healthy middle-aged participants. Among the 80 participants (49.4 ± 6.8&#xa0;year), the baseline NAD was 7.21 [5.5, 10.6] nM. Every 1&#xa0;nM higher baseline NAD level was associated with 0.24% (95%CI: 0.05–0.44) higher lymphocytes, − 0.36% (95% CI: − 0.57 to − 0.14) lower neutrophils, 0.023% (95% CI: 0.011–0.036) higher triglycerides, − 0.009% (95% CI: − 0.015 to − 0.003) lower high-density lipoprotein, 0.02% (95% CI: 0.004–0.035) higher alanine transaminase, 0.01% (95% CI: 0.0003–0.021) aspartate transaminase. Every 1&#xa0;nM increase in the NAD level was associated with an increase in hemoglobin of 0.027% (95% CI: 0.01–0.045), red blood cells (RBC) of 0.025% (95% CI: 0.009–0.042), mean corpuscular hemoglobin concentration of 0.016&#xa0;g/dL (95% CI: 0.008–0.025), and uric acid of 0.02% (95%CI: 0.003–0.038). Higher baseline NAD levels are associated with inflammatory, lipid, and liver profiles. NMN-induced increases in blood NAD are associated with an increase in RBC parameters, potentially indicating enhanced oxygen-carrying capacity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial

  • 期刊论文

  • 发表日期：

    2025年10月29日

查看全文
  • Ajla H. Kuerec,
  • Weilan Wang,
  • Keona D. M. Fokke,
  • Lin Yi,
  • Zhigang Lin,
  • Aditi Vaidya,
  • Sohal Pendse,
  • Sornaraja Thasma,
  • Niranjan Andhalkar,
  • Ganesh Avhad,
  • Vidyadhar Kumbhar,
  • Andrea B. Maier

摘要

To assess associations between blood nicotinamide adenine dinucleotide (NAD) levels and laboratory parameters at baseline and after 60 days of nicotinamide mononucleotide (NMN) supplementation. Post hoc analysis of a randomized, double-blind, clinical trial of daily NMN (300, 600, or 900 mg) or placebo in healthy middle-aged participants. Among the 80 participants (49.4 ± 6.8 year), the baseline NAD was 7.21 [5.5, 10.6] nM. Every 1 nM higher baseline NAD level was associated with 0.24% (95%CI: 0.05–0.44) higher lymphocytes, − 0.36% (95% CI: − 0.57 to − 0.14) lower neutrophils, 0.023% (95% CI: 0.011–0.036) higher triglycerides, − 0.009% (95% CI: − 0.015 to − 0.003) lower high-density lipoprotein, 0.02% (95% CI: 0.004–0.035) higher alanine transaminase, 0.01% (95% CI: 0.0003–0.021) aspartate transaminase. Every 1 nM increase in the NAD level was associated with an increase in hemoglobin of 0.027% (95% CI: 0.01–0.045), red blood cells (RBC) of 0.025% (95% CI: 0.009–0.042), mean corpuscular hemoglobin concentration of 0.016 g/dL (95% CI: 0.008–0.025), and uric acid of 0.02% (95%CI: 0.003–0.038). Higher baseline NAD levels are associated with inflammatory, lipid, and liver profiles. NMN-induced increases in blood NAD are associated with an increase in RBC parameters, potentially indicating enhanced oxygen-carrying capacity.